the human record, read straight
CJC-1295 research: the studies, the numbers, the gaps
A long-acting GHRH analog with a small but precise human evidence base — and a clear honest edge where the data stops.
The design: an albumin-bioconjugate GHRH analog
CJC-1295 began as a chemistry problem: native GHRH is destroyed in minutes by dipeptidylpeptidase-IV. A series of hGRF(1-29) analogs carrying a C-terminal maleimidopropionyl-lysine handle were screened, and the lead candidate combined four DPP-IV-protective substitutions with covalent bioconjugation to serum albumin [1]. In rats, the conjugate produced a 4-fold increase in growth-hormone area-under-the-curve over two hours versus the unconjugated peptide, remained detectable in plasma beyond 72 hours, and was stable to DPP-IV in a cell-free assay [1].
That is the whole trick. The substitutions stop the protease; the albumin link stops clearance. Together they convert a minutes-long peptide into a multi-day one — the molecule the human studies then characterized.
What CJC-1295 does in humans
In healthy adults aged 21 to 61, single subcutaneous doses of 30 or 60 micrograms per kilogram produced dose-dependent 2- to 10-fold increases in mean plasma growth hormone for six days or more, and 1.5- to 3-fold increases in IGF-1 for nine to eleven days [2]. After multiple doses, IGF-1 stayed above baseline for up to 28 days, and the estimated CJC-1295 half-life was 5.8-8.1 days [2].
A second study sharpened the picture. In healthy men aged 20 to 40, a single 60 or 90 microgram-per-kilogram dose raised basal growth hormone roughly 7.5-fold, mean GH by about 46% and IGF-1 by about 45% one week later [3]. The mechanism reaches downstream of the pituitary through the liver: pituitary GH release activates hepatic GH receptors and JAK2/STAT5 signaling, raising IGF-1 [3]. A proteomics study in 11 healthy young men confirmed the axis was engaged, finding reproducible serum-protein shifts that correlated linearly with IGF-1 [5]. Framed as documented research outcomes rather than promises, that is what the literature reports CJC-1295 doing: a sustained, multi-day rise in GH and IGF-1.
Pulsatility persists under continuous stimulation
The most interesting human finding is the one easiest to miss. Growth hormone is normally secreted in pulses; a drug that floods the pituitary with continuous drive might be expected to flatten that rhythm. It did not. Under sustained CJC-1295 stimulation, the frequency and magnitude of pulsatile GH secretion were unaltered — pulsatility persisted [3].
That matters because the pulsatile pattern is thought to carry part of GH's physiological signal. A long-acting analog that preserves the pulses is mechanistically different from a continuous infusion of growth hormone itself. The supporting animal work points the same way: in GHRH-knockout mice, 2 micrograms of CJC-1295 once every 24 hours fully normalized body weight and length, while dosing every 48 to 72 hours was progressively less effective [4].
CJC-1295 within the GHRH-analog class
A GHRH analog is a synthetic molecule that mimics growth-hormone-releasing hormone at its receptor — a class-B G-protein-coupled receptor on pituitary somatotrophs — to stimulate the body's own GH output [10]. CJC-1295 sits in that class alongside sermorelin and the approved drug tesamorelin. A 2025 Nature Reviews Endocrinology review of GHRH and its analogues describes the shared receptor signaling, the rationale for long-acting analog design, and the therapeutic and investigational landscape for the class [10].
CJC-1295 vs sermorelin and the other GHRH analogs
Sermorelin is GHRH(1-29) without the protease-resistant substitutions or albumin handle, so it is short-acting and was historically used in diagnostic and pediatric settings. Tesamorelin is a stabilized GHRH analog approved for HIV-associated lipodystrophy — the closest approved-drug comparator to CJC-1295. The distinction is duration and approval status: CJC-1295 DAC is engineered for a multi-day half-life and is not approved for human use, whereas tesamorelin is approved and dosed daily [9][10].
What the research reports CJC-1295 does
CJC-1295 benefits, reframed as documented outcomes
Reframed away from the language of "benefits," the documented outcomes are narrow and specific. CJC-1295 raises growth hormone and IGF-1 in a dose-dependent, multi-day fashion in healthy volunteers [2][3]. It preserves the natural pulsatile pattern of GH secretion [3]. In knockout mice it restores GH-axis-dependent growth on a once-daily schedule [4].
What the literature does not report is any controlled trial of body composition, strength, recovery, or longevity outcomes in healthy adults. The HIV-visceral-obesity Phase 2 program was discontinued [9]. So the honest summary is two-sided: the endocrine pharmacology is real and reproducible; the clinical-outcome story is largely unwritten. This site keeps both halves on the page.
Where CJC-1295 was found outside the lab
One study underscores how far CJC-1295 traveled beyond its clinical program. Anti-doping chemists used high-resolution LC-MS/MS to structurally identify CJC-1295 as the active ingredient in an unknown "GHRH" pharmaceutical preparation seized in a doping context [6]. The molecule designed in a ConjuChem lab and characterized in two endocrinology studies turned up, years later, as a black-market product — which is part of why detection assays for it are now well established and why it is prohibited at all times under WADA Section S2 [6][9].